This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
Kadcyla is an antibody-drug conjugate engineered to deliver potent chemotherapy directly to HER2-positive cancer cells, potentially limiting damage to healthy tissues. It combines two anti-cancer properties joined together by a stable linker: the HER2-targeting properties of trastuzumab (the active ingredient in Herceptin) and the chemotherapy agent DM1.
KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for:
The treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:
Received prior therapy for metastatic disease, or
Developed disease recurrence during or within six months of completing adjuvant therapy.
The adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
If a patient becomes pregnant while receiving KADCYLA, or within 7 months following the last dose of Kadcyla, please immediately report pregnancy to the local Roche Adverse Event Line at
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.